Menu

FDA Approves Second CAR T-Cell Therapy

The therapy, produced by Kite Pharma and owned by Gilead Sciences, is approved for use against some types of large B-cell lymphomas. 

Oct 19, 2017
Ashley P. Taylor

ISTOCK, 7ACTIVESTUDIOThe Food and Drug Administration yesterday (October 18, 2017) approved the chimeric antigen receptor (CAR) T-cell therapy Yescarta to treat patients with certain types of large B-cell lymphomas who have relapsed or not responded to two other types of cancer treatments. It is the second CAR T-cell therapy approved in the U.S.

“Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases. In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer,” FDA Commissioner Scott Gottlieb says in a statement.

“There will likely be thousands of lives saved in the next few years because of it,” David Maloney, medical director of cellular immunotherapy at Fred Hutchinson Cancer Research Center, tells NBC News.

CAR T-cell therapies work by engineering a patient’s own immune cells to target cancer cells.

See “The CAR T-Cell Race

In August, the FDA approved a CAR T-cell therapy, Kymriah, produced by Novartis, for acute lymphoblastic leukemia. Like Yescarta, Kymriah was also approved only for patients for whom other therapies have twice failed.

Development of the treatment began at the National Cancer Institute, then moved to Kite in 2012, The New York Times reports. Gilead acquired Kite in August. The FDA granted the approval to Kite, which will continue to produce the drug. That process, which takes about 17 days, involves shipping a patient’s cells to Kite’s cell-processing facility in California where they will be engineered, then freezing the cells and shipping them back to the patient’s hospital, according to The New York Times.

Patients with large B-cell lymphoma who were treated with Yescarta had a 51 percent complete remission rate in a multicenter clinical trial, according to the FDA statement.

The treatment comes with the risk of life-threatening side effects, including “high fevers, crashing blood pressure, lung congestion and neurological problems,” The New York Times reports. It also very expensive, with a list price of $373,000, according to a Kite Pharma release.

“Yes, it can pose life threatening problems,” Tina Bureau, who took Yescarta as part of the clinical trial and whose lymphoma is in remission, tells The New York Times. “But when you’re in a situation where your life’s threatened anyway, I don’t feel you have anything to lose.”

See “Marking CAR T-Cell Therapy Safer

“Together, Gilead and Kite will accelerate studies of CAR-T therapy in multiple blood cancers and advance other cell therapy approaches for solid tumors,” David Chang, chief medical officer at Kite, tells The Times of Israel, “with the goal of helping patients with diverse cancers benefit from this new era of personalized cancer therapy.”

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!